Assessment of Biofield Energy Treatment on Liver Health Using Hepatocellular Carcinoma Cell Line (HepG2)

Authors: Dahryn Trivedi, Snehasis Jana

Liver is the main metabolic organ in human. Most of the chemicals are primarily metabolized in the liver followed by excretion of the metabolites from the body. Therefore, there is a high chance of liver damage and most of the peoples are suffering many diseases due to their poor metabolic power of liver. In this context, the present study was performed to find out the potential role of the Biofield Energy (The Trivedi Effect®) Treated test item (DMEM) in HepG2 cell line. The test item was divided into two parts. One part of the test item received Consciousness Energy Healing Treatment by a renowned Biofield Energy Healer, Dahryn Trivedi and the other part defined as the untreated DMEM, where no Biof-ield Treatment was given. Cell viability of the test sample using MTT assay showed 152.8 % viable cells in the Biofield Energy Treated DMEM group, suggested that the test item was nontoxic and safe in nature. The Biofield Energy Treated DMEM showed 12.2 % protection of cells against oxidative stress induced by t-BHP. The level of IL-8 was significantly reduced by 13.71 % in the Biofield Energy Treated DMEM group compared to the TNF-α stimulated control group. Moreover, the level of ALT was significantly (p ≤ 0.001) reduced by 64.16 % in the Biofield Energy Treated DMEM group compared to the t-BHP group. Cholesterol level was significantly reduced by 34.94 % Biofield Energy Treated DMEM group compared to the untreated DMEM group. Besides, the Biofield Energy Treated DMEM group showed 23.19 % increased the level of albumin compared to the untreated DMEM group. Altogether, results suggested that Bio-field Treatment significantly improved liver health and its function. Thus, Consciousness Energy Healing (The Trivedi Effect®) Treatment could be utilized as a hepatoprotectant against several hepatic disorders such as Gilbert’s disease, cirrhosis, steatosis, alcohol abuse, hemochromatosis, Budd-Chiari syndrome, Wilson’s disease, cholangiocarcinoma, etc.

Comments: 7 Pages.

Download: PDF

Submission history

[v1] 2019-03-11 02:20:32

Unique-IP document downloads: 1 times is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. will not be responsible for any consequences of actions that result from any form of use of any documents on this website.

Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.

comments powered by Disqus